T&R Biofab Co. Ltd (246710) - Cash Flow Conversion Efficiency
Based on the latest financial reports, T&R Biofab Co. Ltd (246710) has a cash flow conversion efficiency ratio of 0.002x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩17.53 Million ≈ $11.88K USD) by net assets (₩11.31 Billion ≈ $7.66 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 246710 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
T&R Biofab Co. Ltd - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how T&R Biofab Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
T&R Biofab Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of T&R Biofab Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cheil Grinding
KO:001560
|
0.011x |
|
White Pearl Technology Group B
ST:WPTG-B
|
N/A |
|
TPXIMPACT HOLDINGS LS-01
F:9L7
|
N/A |
|
PharmGen Science Inc
KO:004720
|
0.008x |
|
GenMont Biotech Inc
TW:3164
|
0.034x |
|
TJGC Group Limited
NASDAQ:TJGC
|
-1.130x |
|
Hwacheon Machi
KO:010660
|
-0.024x |
|
GeneFerm Biotechnology Co Ltd
TWO:1796
|
0.002x |
Annual Cash Flow Conversion Efficiency for T&R Biofab Co. Ltd (2015–2024)
The table below shows the annual cash flow conversion efficiency of T&R Biofab Co. Ltd from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of T&R Biofab Co. Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩24.21 Billion ≈ $16.41 Million |
₩-11.73 Billion ≈ $-7.95 Million |
-0.485x | -117.11% |
| 2023-12-31 | ₩31.20 Billion ≈ $21.14 Million |
₩-6.96 Billion ≈ $-4.72 Million |
-0.223x | -48.88% |
| 2022-12-31 | ₩39.26 Billion ≈ $26.61 Million |
₩-5.89 Billion ≈ $-3.99 Million |
-0.150x | +17.34% |
| 2021-12-31 | ₩41.69 Billion ≈ $28.25 Million |
₩-7.56 Billion ≈ $-5.12 Million |
-0.181x | +0.27% |
| 2020-12-31 | ₩46.05 Billion ≈ $31.21 Million |
₩-8.38 Billion ≈ $-5.68 Million |
-0.182x | +12.97% |
| 2019-12-31 | ₩24.76 Billion ≈ $16.78 Million |
₩-5.17 Billion ≈ $-3.51 Million |
-0.209x | -11.74% |
| 2018-12-31 | ₩30.27 Billion ≈ $20.51 Million |
₩-5.66 Billion ≈ $-3.84 Million |
-0.187x | +54.45% |
| 2017-12-31 | ₩9.07 Billion ≈ $6.15 Million |
₩-3.72 Billion ≈ $-2.52 Million |
-0.411x | -40.25% |
| 2016-12-31 | ₩8.85 Billion ≈ $6.00 Million |
₩-2.59 Billion ≈ $-1.76 Million |
-0.293x | +0.24% |
| 2015-12-31 | ₩3.58 Billion ≈ $2.42 Million |
₩-1.05 Billion ≈ $-710.94K |
-0.293x | -- |
About T&R Biofab Co. Ltd
T&R Biofab Co., Ltd. develops and commercializes various regenerative medical technologies. It offers 3D-printed medical devices; and bio-surgical solutions, which includes wound dressing and acellular dermal matrix, as well as biomaterials and biopharmaceuticals. The company was founded in 2013 and is based in Siheung-si, South Korea.